泊马度胺为基础方案治疗复发难治多发性骨髓瘤效果观察  

Efficacy observation of pomalidomide⁃based regimen in treatment of relapsed/refractory multiple myeloma

作　　者：冯友繁[1] 魏小芳 张新莲 张启科[1] 赵丽[3] 伏媛[1] 赵阳阳 黄秀娟[1] 李青芬 Feng Youfan;Wei Xiaofang;Zhang Xinlian;Zhang Qike;Zhao Li;Fu Yuan;Zhao Yangyang;Huang Xiujuan;Li Qingfen(Department of Hematology,Gansu Provincial Hospital,Lanzhou 730000,China;Department of Hematology,the First People's Hospital of Lanzhou,Lanzhou 730050,China;the First Clinical Medicine College of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]甘肃省人民医院血液科,兰州730000 [2]兰州市第一人民医院血液科,兰州730050 [3]兰州大学第一临床医学院,兰州730000

出　　处：《白血病．淋巴瘤》2022年第4期218-222,共5页Journal of Leukemia & Lymphoma

基　　金：兰州市卫生健康科技发展项目(2019-004);甘肃省人民医院院内基金(17GSSY-2)。

摘　　要：目的探讨真实世界中泊马度胺治疗复发难治多发性骨髓瘤(MM)的早期效果和安全性。方法回顾性分析甘肃省人民医院2021年1月至7月收治的15例以泊马度胺为基础方案治疗的复发难治MM患者的临床资料,对其早期疗效和安全性进行评估。结果15例患者中男性8例,女性7例,中位发病年龄60岁(43~83岁);诊断复发、难治中位时间15个月(4~84个月)。15例均接受过以硼替佐米为主的治疗方案;9例接受过来那度胺治疗;7例接受过自体造血干细胞移植。15例均采用泊马度胺联合其他药物(硼替佐米、达雷妥尤单抗、苯达莫司汀、地塞米松、环磷酰胺或来那度胺)的两药或三药方案治疗,中位治疗2个(2~4个)周期。治疗2个周期后评估疗效,总反应率为73%(11/15),其中3例达完全缓解,3例达非常好的部分缓解,5例达部分缓解。9例出现血液学不良反应,其中5例为3~4级,4例为1~2级,其余不良反应均较轻微,可耐受。结论泊马度胺为基础的治疗方案对复发难治MM患者有效,且安全性较好。Objective To investigate the early efficacy and safety of pomalidomide⁃based regimen in relapsed/refractory multiple myeloma(MM)in the real world.Methods The clinical data of 15 patients with relapsed/refractory MM treated with pomalidomide⁃based regimen who were admitted to Gansu Provincial Hospital from January 2021 to July 2021 were retrospectively analyzed,and the early efficacy and safety were also evaluated.Results There were 8 males and 7 females,and the median age of onset of 15 patients was 60 years(43-83 years);the median time for the diagnosis of relapse and refractory was 15 months(4-84 months).All 15 patients previously received bortezomib⁃based treatment regimens,9 patients previously received lenalidomide treatment,and 7 cases received autologous hematopoietic stem cell transplantation.All patients received pomalidomide⁃based regimen combined with two⁃drug or three⁃drug regimen(pomalidomide combined with bortezomib,daratumumab,bendamustine,dexamethasone,cyclophosphamide or lenalidomide).The median treatment cycle was 2 cycles(2-4 cycles).After 2 cycles of treatment,the therapeutic efficacy was evaluated;the overall response rate was 73%(11/15),including 3 cases of complete remission,3 cases of very good partial remission,and 5 cases of partial remission.Hematological toxicity occurred in 9 patients,of which 5 cases had grade 3-4 hematological toxicity,4 cases had grade 1-2 hematological toxicity,and other adverse reactions were mild and tolerable.Conclusion Pomalidomide⁃based regimen is effective and safe for relapsed/refractory MM patients.

关 键 词：多发性骨髓瘤 复发 难治 泊马度胺 药物疗法 联合 

分 类 号：R733.3[医药卫生—肿瘤]